In 2023, QualityMetric (QM) became an IQVIA business. This further enabled us to provide clinical outcome assessment (COA) licensing in addition to leveraging our combined innovative technology solutions and scientific expertise. Since our full integration into IQVIA will soon be complete, it is time to retire the QM brand.
As we remain committed to our same quality licensing and services, we invite you to find the legacy QM COAs you know, in addition to the other 160+ COA offerings on IQVIA's COA Marketplace.
Through our trusted network of U.S.-based linguists and in-country translators, we deliver cross-cultural adaptations and linguistically validated translations of all types of clinical and scientific content. Our specialists cover more than 200 languages across research locations around the world. Working towards absolute conceptual equivalence, cultural appropriateness and content validity, we enable each target population to interpret translated items exactly as intended.
Our translators are not only selected for their linguistic expertise, but also for their breadth of knowledge on end-to-end drug development and country-specific guidelines. Closely following FDA and ISPOR recommended methodology, we align your PRO translations with both regulatory authority requirements and industry best practices in the clinical research space.
In the early stages of PRO development, a translatability assessment can help you determine the suitability of the proposed language. Our process involves the designation of “difficulty ratings” that allow you to easily identify and address any problematic items. We then present our findings and recommendations in a comprehensive report.
We gather translations from multiple consultants who are native speakers of the target language and bilingual in English. Emphasis is placed on conceptual rather than literal equivalence and achieving an appropriate reading level.
Independent forward translations are reconciled into one preliminary form.
This form is translated back into English and evaluated by U.S. researchers and in-house project managers for conceptual equivalence with the original survey.
A clinician review is included for selected instruments to ensure culturally appropriate translation of items containing treatment names and other jargon. Clinician(s) residing in the target country will provide input on the clarity and accuracy of the translation.
Cognitive debriefing interviews are conducted among a sample of native speakers of the target language living in-country to determine clarity, common language usage and conceptual equivalence.
An international harmonization meeting is attended by linguists who are representative of each target language and country. Linguists will be asked to review the existing translation and update any item to ensure conceptual equivalence and consistency across all translations of the same instrument included in the project.
The final translation is proofread by native speakers and formatted for quality assurance.
